NOT KNOWN DETAILS ABOUT SEVITERONEL

Much like TNBC, the position of AR from the management of estrogen receptor-positive (ER+) breast cancer is a location of Lively investigation. AR is expressed in as much as 90% of ER+ tumors and preclinical data indicates that AR expression is linked to resistance to each tamoxifen and aromatase inhibitors in ER+ cell strains [fourteen–16]. Even